

Europe



IABS-EU OFFICE

World Trade Center
Tour Oxygène
Boulevard Vivier Merle
69393 Lyon
Cedex 03
FRANCE

CONTACT OUR TEAM:

Dr. Joris Vandeputte
Executive Director, IABS
Chairman, IABS-EU
Tel: +32 (0) 65 75 52 85
Cell: +32 (0) 473 52 83 92
Email: joris.vandeputte@iabs.org

Abigail Charlet
Director IABS-EU Office
Tel: +33 (0) 4 26 02 18 10
Cell: +33 (0) 688 07 18 24
Email: abbie.charlet@iabs.org

Dr. Johan Vanhemelrijck
Advisor
Tel: + 32 (0) 2 706 81 77
Cell: +32 (0) 475 30 62 57
Email: johan.vanhemelrijck@iabs.org

www.iabs.org

Europe



International Alliance for Biological Standardization

*Your essential partner in support of EU
projects focused on innovative research
and development of biologicals
from vaccines up to cells and tissues*

DISSEMINATION OF RESEARCH RESULTS

BRIDGE BETWEEN PUBLIC AND
PRIVATE SECTORS

MORE THAN 130
INTERNATIONAL CONFERENCES
ORGANISED TO DATE

BUILDING CONSENSUS ACROSS
STAKEHOLDER SPECTRUM

SCIENTIFIC JOURNAL
"BIOLOGICALS"

Europe



International Alliance for Biological Standardization

IABS is an essential partner in support of biological research projects on innovative research and development of biologicals from vaccines up to cells and tissues.

IABS can be a reliable and decisive partner in projects involving biologicals by its ability to pool worldwide expertise on biological standardisation, an essential and integral part of early development.

Moreover, IABS, through the organisation of international conferences, involves the biological communities of regulatory authorities, industry and academia as essential partners in building consensus on norms and standards, and dissemination of their availability at the international level.

The International Alliance for Biological Standardization (IABS), located in Geneva, Switzerland, and in Lyon, France as *IABS-EU*, is a non-profit association recognized as an NGO by the World Health Organization. The mission of IABS is to contribute to the scientific and medical advancement of biologicals by facilitating communication among those who develop, produce and regulate biological products for human and animal health.

MARK THE UPCOMING IABS CONFERENCES AND WORKSHOPS IN YOUR CALENDAR:

- *Statistical and Data Management Approaches for Biotechnology Drug Development*
August 27 - 28, 2014 - USP Meeting Center, Rockville, Maryland
- *Human Challenge Trials in Vaccine Development: Scientific and Regulatory Issues*
September 29 - October 1, 2014 - EDQM, Strasbourg, France

A unique feature of IABS is that it acts as a neutral meeting point for the major stakeholders - regulators, academia, and industry- to consider the impact of regulatory requirements on innovation, with the objective of identifying sections that may require modification. IABS realizes this overall objective as follows:

- IABS brings together an outstanding and diverse group of experts, from regulatory agencies, industry, academia, all of whom are at the forefront of biologicals research and development, including the cell therapy field.
- IABS increases awareness of the diverse views of global stakeholders.
- IABS initiates, organises and promotes continued international dialogue and exchange of information and points of view in the evolving field of biologicals.
- IABS generates a common international recognition of the essential scientific elements for research and early product development, evaluation and control of biologicals including cell therapy products.
- IABS identifies very critical points/issues to be resolved, improved, and/or developed in terms of science-based regulation in order to facilitate the availability of products globally important to public health in a rational and timely manner.
- IABS publishes the scientific journal *BIOLOGICALS* as an essential dissemination tool for research and information in this field.
- IABS facilitates decision-making based on helping to ensure an efficient standard-setting basis in the regulatory approval process. Including IABS as a partner is therefore critically important also for early research projects.
- IABS is especially interested in improving the predictability of early efficacy and safety research on biological products. This is in line with efforts to reduce late fallout and costs of phase 3 clinical trials.
- Please visit our website at <http://www.iabs.org> to find out if, how and with whom IABS could be a potential partner in EU research projects.